<?xml version="1.0" encoding="UTF-8"?>
<ref id="B83-ijms-21-05145">
 <label>83.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sharpe</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Gilbride</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Allen</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Belij-Rammerstorfer</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Bissett</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Ewer</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Lambe</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>The early landscape of COVID-19 vaccine development in the UK and rest of the world</article-title>
  <source>Immunology</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1111/imm.13222</pub-id>
 </element-citation>
</ref>
